Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

284.27 +0.18 (+0.06%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
Upgrades 
Via Benzinga
United Therapeutics Stops Late-Stage Tyvaso Study In Lung Disease
Via Benzinga
United Therapeutics: Return On Capital Employed Overview
  
Via Benzinga
Expert Ratings for United Therapeutics
Within the last quarter, United Therapeutics (NASDAQ:UTHR) has observed the following analyst ratings: 
Via Benzinga
United Therapeutics Announces First Patient Enrolled in Phase 3 TETON 2 Study of Tyvaso in Patients With Idiopathic Pulmonary Fibrosis
From United Therapeutics Corporation
Via Business Wire
Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market
Following insider buying is a savvy way for retail investors to profit even when a bear market is raging on Wall Street. Here are 15 stocks. 
Via InvestorPlace
United Therapeutics Releases Its Annual Corporate Responsibility Report and Inaugural Public Benefit Report
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Prevails in Dry Powder Inhaler Patent Litigation
From United Therapeutics Corporation
Via Business Wire
United Therapeutics to Feature Clinical Data at the European Society of Cardiology Congress 2022 and the European Respiratory Society International Congress 2022
From United Therapeutics Corporation
Via Business Wire
New Drugs in Pipeline for Hypertension, the Silent Global Pandemic
Via Investor Brand Network
New Drugs in Pipeline for Hypertension, the Silent Global Pandemic
NetworkNewsWire Editorial Coverage New York, NY – August 10, 2022 – In medicine, there is a term called “clinical inertia,” or the case of what someone doesn’t know — or what they ignore — could kill... 
Via FinancialNewsMedia
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review
The Nasdaq and small caps rose while the S&P 500 is hitting resistance. 
Via Investor's Business Daily
United Therapeutics Corporation Reports Second Quarter 2022 Financial Results
From United Therapeutics Corporation
Via Business Wire
Earnings Outlook For United Therapeutics
United Therapeutics (NASDAQ:UTHR) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that United... 
Via Benzinga
United Therapeutics Corporation to Report Second Quarter 2022 Financial Results Before the Market Opens on Wednesday, August 3, 2022
From United Therapeutics Corporation
Via Business Wire
7 Best Pharmaceutical Stocks to Buy Now
These investments represent the best pharmaceutical stocks. Each offers incredible upside potential in the post-pandemic world. 
Via InvestorPlace
Swing Trading Stock Watchlist For The Week Of July 11 And Beyond
The stock market's health is improving, but a likely bottom has not been confirmed yet. That means I’m buying some stocks (swing trades), but I'm not loading up yet. Let's see what I'm looking at. 
Via Talk Markets
7 Biotech Stocks With Key Catalysts Coming in July
Biotech stocks have had a rocky few months, but many are on the mend. These picks should provide investors both flexibility and growth. 
Via InvestorPlace
Buy These 3 Low-Beta Stocks To Sail Through A Choppy Market
Creating a portfolio of low-beta stocks is of utmost importance since the securities will deliver healthy returns and provide a shield against volatile market conditions. 
Via Talk Markets
Corcept Stock Near Buy Point; Strength Rating Jumps To 91
The new 91 RS Rating means that Corcept stock has outperformed 90% of all other stocks over the past year. 
Via Investor's Business Daily
Will Investors Notice Exciting Sign On United Therapeutics's Chart?
If history is any guide, there may be good fortune ahead for shares of United Therapeutics (NASDAQ:UTHR). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish... 
Via Benzinga
United Therapeutics Provides an Update on Its Organ Printing Programs
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Present at the Jefferies Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
Short Volatility Alert: United Therapeutics Corporation
On Wednesday, shares of United Therapeutics Corporation (NASDAQ: UTHR) experienced volatile short activity. After the activity, the stock price went up 4.31% to $228.39. The... 
Via Benzinga
United Therapeutics Stock Sees RS Rating Jump To 89; Earns 'Blue Dot'
United Therapeutics stock had its Relative Strength (RS) Rating upgraded to 89 Tuesday, from 71 a day earlier. 
Via Investor's Business Daily
The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
United Therapeutics Announces FDA Approval of Tyvaso DPI™
From United Therapeutics Corporation
Via Business Wire
United Therapeutics's Return on Invested Capital Insights
According to Benzinga Pro, during Q1, United Therapeutics (NASDAQ:UTHR) earned $239.90 million, a 113.81% increase from the preceding quarter. United Therapeutics also posted a total of $461.90 million... 
Via Benzinga
7 Biotech Stocks With Key Catalysts for May
The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. 
Via InvestorPlace
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.